CELC

$86.60-$5.48 (-5.95%)live

Compare

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institution

Market cap

$4.5B

49M shares

52-week range

$44.42 – $151.02

40% from low

Sector

SERVICES-MEDICAL LABORATORIES

Exchange

NASDAQ

Change+$65.66

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$40M	+3181.4%	$-4.22	$-4.62–$-4.00	—	5
2027	$392M	+882.8%	$-0.50	$-68.41–$42.66	—	5
2028	$716M	+82.6%	$3.26	$0.27–$6.66	26.5×	7
2029	$1.1B	+60.2%	$7.42	$2.81–$13.81	11.7×	2

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 4 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-13	$-1.16	$-1.44	-24.1%
2026-05-14	$-1.04	$-0.97	+6.7%
2026-03-25	$-1.06	$-0.97	+8.5%
2025-11-12	$-1.02	$-0.92	+9.8%
2025-08-14	$-0.90	$-1.04	-15.6%
2025-05-14	$-0.95	$-0.86	+9.5%
2025-03-31	$-0.72	$-0.85	-18.1%
2024-11-14	$-0.65

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
CELCCelcuity Inc.	$86.60	-5.95%	$4.2B	—
AAPGAscentage Pharma Group International	$19.00	+0.16%	$1.8B	—
APGEApogee Therapeutics, Inc.	$134.45	-0.07%	$8.3B	—
CGONCG Oncology Inc.	$74.71	-2.96%	$6.6B	—
CNTACentessa Pharmaceuticals plc	$40.50	+0.00%

Celcuity Inc. Common Stock

Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.

www.celcuity.com

Employees: 155
IPO / List date: Sep 20, 2017
HQ: MINNEAPOLIS, MN

Held by traders on TradeandTell

No one on the platform currently holds CELC.

Super investors & insiders

Institutions holding (13F)

Institution	Shares	Reported
Renaissance Technologiesas of 2025-09-30	194,800	$9.6M

Insider activity (SEC Form 4)

Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded CELC yet.